Clinical Trial Search

Primary: To Assess the Safety & Tolerability of 20089 TA (6.9 mg or 13.8 mg) When Used Adjunctively With Lucentis 0.5 mg in Subjects With Sub-foveal Neovascular AMD — 0…

Primary: Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline — 45; 71 days to flare — p=0.2738

Primary: A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged. — 58; 58; 54; 43 participants

Primary: Number With Observed Adverse Side Effects — 26; 25; 15; 14 participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants

Primary: Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12). — 40; 6 Percentage reduction

Primary: Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Approximately 1 Week — 10; 21 participants — p=0.02

Primary: Total Volume of All Crystalloid Given for Early Resuscitation (Feasibility) — 2.04; 1.04; 1 liters

Primary: Freedom From Seizure — 7 individuals

Primary: Days of Work and Work-related Activity — 8.3; 8.7; 6.6; 9.0 days

Primary: Change in Depression Symptom Severity From Baseline to Study Endpoint — -20.9 Units on a scale

Primary: Number of Participants With Successful Engraftment at Day 100 — 27; 23 participants

Primary: Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled — 30 Eligible persons screened who enrolled

Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658